Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2023

01-05-2023 | Interstitial Nephritis | Case report

Naproxen

Acute interstitial nephritis and minimal change disease: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Bonifant GC, et al. NSAID Induced AIN and Minimal Change Disease with Complete Resolution. Journal of the American Society of Nephrology 27: 998A-999A, Nov 2016 [abstract]
Metadata
Title
Naproxen
Acute interstitial nephritis and minimal change disease: case report
Publication date
01-05-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-39539-z

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Irinotecan/temozolomide

Case report

Mesalazine

Case report

Cyclophosphamide/rituximab

Case report

Folinic acid/methotrexate

Case report

Selpercatinib

Case report

Hyaluronic acid/hyaluronidase